GNTA Share Price Performance
Recent GNTA News & Updates
No updates
Genenta Science S.p.A. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.49
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Genenta Science S.p.A. Competitors
About GNTA
- Founded
- 2014
- Employees
- 13
- CEO
- WebsiteView website
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Italian Market Performance
- 7 Days: -2.1%
- 3 Months: 3.8%
- 1 Year: 22.3%
- Year to Date: 14.4%
Over the last 7 days, the market has dropped 2.1%, driven by a decline of 9.9% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 22% over the past year. Earnings are forecast to grow by 8.0% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading